A probability/risk matrix of febrile neutropenia to select patients for G-CSF primary prophylaxis

被引：0
|
作者：
Ramchandani Vaswani, A. [1 ]
Faez, L. [2 ]
Selvi Miralles, M. [3 ]
Antonio-Rebollo, M. [4 ]
Font Puig, C. [3 ]
Espinosa Arranz, J. [5 ]
Biosca, M. [6 ]
Vicente Rubio, E. [7 ,8 ]
Jimenez Fonseca, P. [2 ]
Carmona-Bayonas, A.
机构：
[1] Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain
[2] Hosp Cent Asturias, Oviedo, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] ICO Duran & Reynals, Barcelona, Spain
[5] Hosp Gen Ciudad Real, Ciudad Real, Spain
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] Hosp Univ Insular Gran Canaria, Barcelona, Spain
[8] Hosp Univ Morales Meseguer, Murcia, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1326
引用
收藏
页码：S275 / S276
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
    Younis, T.
    Rayson, D.
    Jovanovic, S.
    Skedgel, C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (03) : 425 - 432
  • [42] G-CSF prophylaxis of febrile neutropenia and infections after chemotherapy [G-CSF-Prophylaxe von febriler Neutropenie und Infektionen nach Chemotherapie]
    Link H.
    [J]. Der Onkologe, 2014, 20 (3): : 268 - 270
  • [43] Assessing febrile neutropenia outcomes in patients receiving primary versus secondary prophylactic G-CSF treatment therapy with intermediate neutropenic risk chemotherapy regimens
    Goodin, Claire
    Ratliff, Patrick
    Cottingham, Lauren
    Shely, Ryan
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1568 - 1572
  • [44] Is It Safe to Use Long-Acting G-CSF for Febrile Neutropenia Prophylaxis in COVID-19 Pandemic? Reply
    Innocenti, Federico
    [J]. JCO ONCOLOGY PRACTICE, 2021, 17 (07)
  • [45] Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer
    Suzuki, Kanako
    Sasada, Shinsuke
    Kimura, Yuri
    Emi, Akiko
    Kadoya, Takayuki
    Okada, Morihito
    [J]. ANTICANCER RESEARCH, 2022, 42 (12) : 5945 - 5949
  • [46] Primary G-CSF prophylaxis following docetaxel treatment
    Aalbers, A.
    [J]. NETHERLANDS JOURNAL OF MEDICINE, 2019, 77 (09): : 304 - 304
  • [47] G-CSF and GM-CSF in Neutropenia
    Mehta, Hrishikesh M.
    Malandra, Michael
    Corey, Seth J.
    [J]. JOURNAL OF IMMUNOLOGY, 2015, 195 (04): : 1341 - 1349
  • [48] Is it appropriate to select patients for primary prophylactic use of pegfilgrastim based on the risk of febrile neutropenia?
    Narui, Kazutaka
    Ishikawa, Takashi
    Takashima, Ikumi
    Kashiwabara, Kosuke
    Uemura, Yukari
    Kikawa, Yuichiro
    Taira, Naruto
    Mukai, Hirofumi
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [49] G-CSF receptor mutations in patients with congenital neutropenia
    Germeshausen, Manuela
    Skokowa, Julia
    Ballmaier, Matthias
    Zeidler, Cornelia
    Welte, Karl
    [J]. CURRENT OPINION IN HEMATOLOGY, 2008, 15 (04) : 332 - 337
  • [50] Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation
    Wang, Xiaoning
    Ren, Juan
    Liang, Xiao
    He, Pengcheng
    [J]. HEMATOLOGY, 2021, 26 (01) : 950 - 955
12345